$BMRA

BIOMERICA INC

CIK:0000073290|SEC Filings

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended
	Aug. 31, 2026	Aug. 31, 2025
Income Statement [Abstract]
Net sales	$ 1,265,000	$ 1,380,000
Cost of sales	(1,162,000)	(956,000)
Gross profit	103,000	424,000
Operating expenses:
Selling, general, and administrative	1,124,000	1,330,000
Research and development	206,000	212,000
Total operating expenses	1,330,000	1,542,000
Loss from operations	(1,227,000)	(1,118,000)
Other income:
Dividend, interest, and other income	1,000	1,123,000
Total other income	1,000	1,123,000
(Loss) income before income taxes	(1,226,000)	5,000
Provision for income taxes	(6,000)	(3,000)
Net (loss) income	$ (1,232,000)	$ 2,000
Basic net (loss) income per common share	$ (0.37)	$ 0.00
Diluted net (loss) income per common share	$ (0.37)	$ 0.00
Weighted-average common shares outstanding:
Basic	3,295,939	2,638,699
Diluted	3,295,939	2,638,699
Other comprehensive (loss) income, net of tax:
Foreign currency translation adjustment	$ (4,000)	$ 2,000
Comprehensive (loss) income	$ (1,236,000)	$ 4,000

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Aug. 31, 2026	Aug. 31, 2025
Cash flows from operating activities:
Net (loss) income	$ (1,232,000)	$ 2,000
Adjustments to reconcile net (loss) income to net cash used in operating activities:
Depreciation and amortization	15,000	20,000
Provision for expected credit losses	3,000	38,000
(Recovery of) provision for excess and obsolete inventory	(24,000)	7,000
Share-based compensation	134,000	133,000
Amortization of operating lease right-of-use assets	64,000	82,000
Changes in assets and liabilities:
Accounts receivable	(115,000)	(512,000)
Inventories	97,000	10,000
Prepaid expenses and other current assets	71,000	87,000
Other assets	2,000	5,000
Accounts payable and accrued expenses	216,000	10,000
Accrued compensation	60,000	(63,000)
Advances from customers	(36,000)	(1,000)
Reduction in lease liabilities	(57,000)	(86,000)
Net cash used in operating activities	(802,000)	(268,000)
Cash flows from financing activities:
Gross proceeds from sale of common stock	2,231,000	939,000
Costs from sale of common stock		(19,000)
Net cash provided by financing activities	2,231,000	920,000
Effect of exchange rate changes on cash	(4,000)	2,000
Net increase in cash and cash equivalents	1,425,000	654,000
Cash and cash equivalents at beginning of period	1,308,000	2,399,000
Cash and cash equivalents at end of period	2,733,000	3,053,000
Cash paid during the period for:
Income taxes	6,000	3,000
Non-cash investing and financing activities:
Common stock issuance costs accrued and unpaid and charged against additional paid-in capital	111,000
Deferred offering costs		8,000
Write-off of property and equipment, cost	7,000
Write-off of property and equipment, accumulated depreciation	$ 7,000

Condensed Consolidated Balance Sheets - USD ($)	Aug. 31, 2026	May 31, 2026
Current Assets:
Cash and cash equivalents	$ 2,733,000	$ 1,308,000
Accounts receivable, net	897,000	785,000
Inventories, net	1,634,000	1,707,000
Prepaid expenses and other current assets	145,000	216,000
Total current assets	5,409,000	4,016,000
Property and equipment, net	68,000	78,000
Operating lease right-of-use assets, net	1,809,000	1,873,000
Investments	500,000	500,000
Intangible assets, net	204,000	209,000
Other assets	81,000	83,000
Total Assets	8,071,000	6,759,000
Current Liabilities:
Accounts payable and accrued expenses	1,498,000	1,171,000
Accrued compensation	552,000	492,000
Advances from customers	47,000	83,000
Operating lease liabilities, current portion	240,000	235,000
Total current liabilities	2,837,000	2,481,000
Operating lease liabilities, net of current portion	1,586,000	1,648,000
Total Liabilities	4,423,000	4,129,000
Commitments and contingencies (Note 6)
Shareholders’ Equity:
Preferred stock, value
Common stock, $0.08 par value; 300,000,000 and 25,000,000 shares authorized, and 4,598,968 and 3,195,263 shares issued and outstanding, as of August 31, 2026 and May 31, 2026, respectively	368,000	255,000
Additional paid-in capital	61,567,000	59,426,000
Accumulated other comprehensive loss	(112,000)	(108,000)
Accumulated deficit	(58,175,000)	(56,943,000)
Total Shareholders’ Equity	3,648,000	2,630,000
Total Liabilities and Shareholders’ Equity	8,071,000	6,759,000
Series A Preferred Stock [Member]
Shareholders’ Equity:
Preferred stock, value
Related Party [Member]
Current Liabilities:
Secured promissory note payable – related party	$ 500,000	$ 500,000